Management and Prevention Strategies for Community-Acquired Pneumonia in the Gulf Corporation Council

References

• Ioachimescu OC, Ioachimescu AG, Iannini PB: Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae : a 5-year experience. Int J Antimicrob Agents 2004, 24(5):485–490.
   Google Scholar
• Niederman MS, Feldman C, Richards GA: Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006, 27(1):9–11.
   Google Scholar
• Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243–250.
   Google Scholar
• Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377–382.
   Google Scholar
• Man SY, Lee N, Ip M, Antonio GE, Chau SS, Mak P, et al: Prospective comparison of three predictive rules for assessing severity of community acquired pneumonia in Hong Kong. Thorax 2006.
   Google Scholar
• Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A: Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006, 27(1):151–157.
   Google Scholar
• Bauer TT, Ewig S, Marre R, Suttorp N, Welte T: CRB- 65 predicts death from community-acquired pneumonia. J Intern Med 2006, 260(1):93–101.
   Google Scholar
• Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV: A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006, 61(5):419–424.
   Google Scholar
• Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002, 166(5):717–723.
   Google Scholar
• Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163(7):1730–1754.
   Google Scholar
• Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A: Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005, 40(9):1288–1297.
   Google Scholar
• Barlow G, Nathwani D, Williams F, Ogston S, Winter J, Jones M, et al: Reducing door-to-antibiotic time in communityacquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis. Thorax 2007, 62(1):67–74.
   Google Scholar
• Niederman MS, Ahmed QA: Community-acquired pneumonia in elderly patients. Clin Geriatr Med 2003, 19(1):101–120.
   Google Scholar
• Pimentel L, McPherson SJ: Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. Emerg Med Clin North Am 2003, 21(2):395–420.
   Google Scholar
• Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG: Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004, 164(6):637–644.
   Google Scholar
• Leroy O, Saux P, Bedos JP, Caulin E: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005, 128(1):172–183.
   Google Scholar
• Balkhy HH, Memish ZA, Shibl A, Elbashier A, Osoba A: In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia. East Mediterr Health J 2005, 11(1-2):36–44.
   Google Scholar
• Amsden GW: Treatment of Legionnaires’ disease. Drugs 2005, 65(5):605–614.
   Google Scholar
• Kraus CN, Zalkikar J, Powers JH: Levofloxacin and macrolides for treatment of legionnaires disease: multiple comparisons give few answers. Clin Infect Dis 2005, 41(3):416; author reply 416–417.
   Google Scholar
• Sabria M, Pedro-Botet ML, Gomez J, Roig J, Vilaseca B, Sopena N, Banos V: Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005, 128(3):1401–1405.
   Google Scholar
• Moran G: Approaches to treatment of community acquired pneumonia in the Emergency Department and the appropriate role of fluoroquinolones. J Emerg Med 2006, 30(4):377–387.
   Google Scholar
• Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR: In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother 2005, 56(2):353–359.
   Google Scholar
• Bernstein JM: Treatment of community-acquired pneumonia— IDSA guidelines. Infectious Diseases Society of America. Chest 1999, 115(3 Suppl):9S–13S.
   Google Scholar
• Singh A: Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. Clin Infect Dis 2007, 45(1):133; author reply 134–135.
   Google Scholar
• Shibl AM: Patterns of macrolide resistance determinants among S. pyogenes and S. pneumoniae isolates in Saudi Arabia. J Int Med Res 2005, 33(3):349–355.
   Google Scholar
• Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H: Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo- controlled study. Lancet 2007, 369(9560):482–490.
   Google Scholar
• Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161(15):1837–1842.
   Google Scholar
• Soreth J, Cox E, Kweder S, Jenkins J, Galson S: Ketek—the FDA perspective. N Engl J Med 2007, 356(16):1675–1676.
   Google Scholar
• Ross DB: The FDA and the case of Ketek. N Engl J Med 2007, 356(16):1601–1604.
   Google Scholar
• Segreti J, House HR, Siegel RE: Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005, 118 Suppl 7A:21S–28S.
   Google Scholar
• Marrie TJ: Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia. Chemotherapy 2004, 50 Suppl 1:11–15.
   Google Scholar
• Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG: A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. Jama 2000, 283(6):749–755.
   Google Scholar
• Drews TD, Temte JL, Fox BC: Community-associated methicillin-resistant Staphylococcus aureus: review of an emerging public health concern. Wmj 2006, 105(1):52–57.
   Google Scholar
• Pfaller MA, Jones RN: Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002, 44(1):77–84.
   Google Scholar
• Enayet I, Nazeri A, Johnson LB, Riederer K, Pawlak J, Saravolatz LD: Community-associated methicillin-resistant Staphylococcus aureus causing chronic pneumonia. Clin Infect Dis 2006, 42(7):e57–60.
   Google Scholar
• Levison ME, Fung S: Community-associated methicillinresistant Staphylococcus aureus: reconsideration of therapeutic options. Curr Infect Dis Rep 2006, 8(1):23–30.
   Google Scholar
• Frazee BW, Salz TO, Lambert L, Perdreau-Remington F: Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia in an immunocompetent young adult. Ann Emerg Med 2005, 46(5):401–404.
   Google Scholar
• Slama TG, Amin A, Brunton SA, File TM, Jr., Milkovich G, Rodvold KA, et al. A clinician’s guide to the appropriate and accurate use of antibiotics: the Council for Appropriate and Rational Antibiotic Therapy (CARAT) criteria. Am J Med 2005, 118 Suppl 7A:1S–6S.
   Google Scholar
• Balkhy HH, Memish ZA, Almuneef MA, Cunningham GC, Francis C, Fong KC, et al: Methicillin-Resistant Staphylococcus aureus: a 5-year review of surveillance data in a tertiary care hospital in Saudi Arabia Infect Control Hosp Epidemiol 2007, 28:976–982.
   Google Scholar
• Scalera NM, File TM, Jr.: How long should we treat community-acquired pneumonia? Curr Opin Infect Dis 2007, 20(2):177–181.
   Google Scholar
• Qazi S: Short-course therapy for community-acquired pneumonia in paediatric patients. Drugs 2005, 65(9):1179–1192.
   Google Scholar
• Kuzman I, Dakovic-Rode O, Oremus M, Banaszak AM: Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. J Chemother 2005, 17(6):636–642.
   Google Scholar
• Kolditz M, Halank M, Hoffken G: Short-course antimicrobial therapy for community-acquired pneumonia. Treat Respir Med 2005, 4(4):231–239.
   Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44 Suppl 2:S27–72.
   Google Scholar
• Memish ZA, Shibl AM, Ahmed QA: Guidelines for the management of community-acquired pneumonia in Saudi Arabia: a model for the Middle East region. Int J Antimicrob Agents 2002, 20 Suppl 1:S1–12.
   Google Scholar
• Swainston Harrison T, Keam SJ: Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US. Drugs 2007, 67(5):773–792.
   Google Scholar
• Drehobl MA, De Salvo MC, Lewis DE, Breen JD: Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community- acquired pneumonia in adults. Chest 2005, 128(4):2230–2237.
   Google Scholar
• Vergis EN, Indorf A, File TM, Jr., Phillips J, Bates J, Tan J, et al: Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000, 160(9):1294–1300.
   Google Scholar
• Greig J, Jenks P: More on pneumonia: treatment of MRSA in community acquired pneumonia. Bmj 2006, 332(7553):1334.
   Google Scholar
• Bradley SF: Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 2005, 26(6):643–649.
   Google Scholar
• El Solh AA, Aquilina AT, Gunen H, Ramadan F: Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004, 52(2):224–229.
   Google Scholar
• Janssens JP: Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 2005, 11(3):226–230.
   Google Scholar
• El Solh A, Pineda L, Bouquin P, Mankowski C: Determinants of short and long term functional recovery after hospitalization for community-acquired pneumonia in the elderly: role of inflammatory markers. BMC Geriatr 2006, 6:12.
   Google Scholar
• Schmidt-Ioanas M, Lode H: Treatment of pneumonia in elderly patients. Expert Opin Pharmacother 2006, 7(5):499–507.
   Google Scholar
• Fein AM: Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis 1999, 28(4):726–729.
   Google Scholar
• Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000, 7(5):371–382.
   Google Scholar
• Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000, 31(2):383–421.
   Google Scholar
• Marras TK, Gutierrez C, Chan CK: Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest 2000, 118(5):1339–1343.
   Google Scholar
• Bantar C, Bavestrello L, Curcio D, Jasovich A, Absi R, Bagnulo H, et al: Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur). J Chemother 2002, 14, Suppl 4:1–22.
   Google Scholar
• Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, et al: Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000, 182(3):840–847.
   Google Scholar
• Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ: Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002, 162(9):1059–1064.
   Google Scholar
• Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, et al: Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004, 38(11):1570–1578.
   Google Scholar
• Farr BM, Sloman AJ, Fisch MJ: Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991, 115(6):428–436.
   Google Scholar
• Yoshimoto A, Nakamura H, Fujimura M, Nakao S: Severe community-acquired pneumonia in an intensive care unit: risk factors for mortality. Intern Med 2005, 44(7):710–716.
   Google Scholar
• Mohamed AR, Evans DA: The spectrum of pneumonia in 1983 at the Riyadh Armed Forces Hospital. J Infect 1987, 14(1):31–37.
   Google Scholar
• Alzeer A, Mashlah A, Fakim N, Al-Sugair N, Al- Hedaithy M, Al-Majed S, Jamjoom G: Tuberculosis is the commonest cause of pneumonia requiring hospitalization during Hajj (pilgrimage to Makkah). J Infect 1998, 36(3):303–306.
   Google Scholar
• Al-Ghamdi SM, Akbar HO, Qari YA, Fathaldin OA, Al- Rashed RS: Pattern of admission to hospitals during muslim pilgrimage (Hajj). Saudi Med J 2003, 24(10):1073–1076.
   Google Scholar
• Avnon LS, Jotkowitz A, Smoliakov A, Flusser D, Heimer D: Can the routine use of fluoroquinolones for community- acquired pneumonia delay the diagnosis of tuberculosis? A salutary case of diagnostic delay in a pilgrim returning from Mecca. Eur J Intern Med 2006, 17(6):444–446.
   Google Scholar
• Ahmed QA, Arabi YM, Memish ZA: Health risks at the Hajj. Lancet 2006, 367(9515):1008–1015.
   Google Scholar
• Al-Shehry AM, Al-Khan AA: Pre-Hajj health related advice, Makkah. Saudi Epidemiol Bull 1999, 6(4):29–31.
   Google Scholar
• Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN: Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007, 167(1):53–59.
   Google Scholar
• Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al: Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006, 61(3):189–195.
   Google Scholar
• Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J: Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006, 42(8):1093–1101.
   Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodriguez T, Llor C: Protective effects of the 23- valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006, 43(7):860–868.
   Google Scholar
• Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, Plouffe JF, Cetron MS, Butler JC: Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. Jama 1997, 278(16):1333–1339.
   Google Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG: Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003, 138(12):960–968.
   Google Scholar
• Frayha HH, Al Mazrou YY: Vaccination against invasive pneumococcal disease in Saudi Arabia: where do we stand? Ann Saudi Med 2005, 25(2):90–93.
   Google Scholar
• Memish ZA, Balkhy HH, Shibl AM, Barrozo CP, Gray GC: Streptococcus pneumoniae in Saudi Arabia: antibiotic resistance and serotypes of recent clinical isolates. Int J Antimicrob Agents 2004, 23(1):32–38.
   Google Scholar
• Ahmed K, Martinez G, Wilson S, Yoshida R, Dhar R, Mokaddas E, et al: The prevalence and clonal diversity of penicillin-resistant Streptococcus pneumoniae in Kuwait. Epidemiol Infect 2000, 125(3):573–581.
   Google Scholar
• Adhami N, Arabi Y, Raees A, Al-Shimemeri A, Ur- Rahman M, Memish ZA: Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review. Respirology 2006, 11(4):437–441.
   Google Scholar
• Abba AA, Al-Khuwaitir TS, Al-Moghairi AM, Garg H: Presentation and outcome of varicella pneumonia in adults. Saudi Med J 2005, 26(2):338–340.
   Google Scholar
• Ahmed R, Ahmed QA, Adhami NA, Memish ZA: Varicella pneumonia: another ‘steroid responsive’ pneumonia? J Chemother 2002, 14(2):220–222.
   Google Scholar
• Almuneef M, Dillon J, Abbas MF, Memish Z: Varicella zoster virus immunity in multinational health care workers of a Saudi Arabian hospital. Am J Infect Control 2003, 31(6):375–381.
   Google Scholar
• Almuneef M, Memish ZA, Abbas ME, Balkhy HH: Screening healthcare workers for varicella-zoster virus: can we trust the history? Infect Control Hosp Epidemiol 2004, 25(7):595–598.
   Google Scholar
• Almuneef M, Memish ZA, Balkhy HH, Alotaibi B, Helmy M: Chickenpox complications in Saudi Arabia: Is it time for routine varicella vaccination? Int J Infect Dis 2006, 10(2):156–161.
   Google Scholar
• Almuneef MA, Memish ZA, Balkhy HH, Otaibi B, Helmi M: Seroprevalence survey of varicella, measles, rubella, and hepatitis A and B viruses in a multinational healthcare workforce in Saudi Arabia. Infect Control Hosp Epidemiol 2006, 27(11):1178–1183.
   Google Scholar
• Memish ZA, Oni GA, Bannatyne RM, Qasem L: The cost-saving potential of prevaccination antibody tests when implementing a mass immunization program. Mil Med 2001, 166(1):11–13.
   Google Scholar
• Smith NM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, Strikas RA: Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-10):1–42.
   Google Scholar
• Gatrad AR, Shafi S, Memish ZA, Sheikh A: Hajj and the risk of influenza. Bmj 2006, 333(7580):1182–1183.
   Google Scholar
• Rashid H, Shafi S, Bashir HE, Haworth E, Memish ZA, Ali KA, Booy R: Influenza and the Hajj: defining influenza-like illness clinically. Int J Infect Dis 2007. May 29: Epub ahead of print.
   Google Scholar
• Shafi S, Rashid H, Ali K, El Bashir H, Haworth E, Memish ZA, Booy R: Influenza vaccine uptake among British Muslims attending Hajj, 2005 and 2006. Bmj 2006, 333(7580):1220.
   Google Scholar
• Granich R, Binkin N, Jarvis W, Simone P, Rieder H, Espinal M, Kumaresan J: World Health Organization guidelines for prevention of tuberculosis in healthcare facilities in countries with limited resources World Health Organization 1999:1–50.
   Google Scholar
• Jensen PA, Lambert LA, Iademarco MF, Ridzon R: Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005, 54(17):1–141.
   Google Scholar
• Ramirez J: Multicenter, multinational observational studies: a new approach to studying community-acquired pneumonia. Respir Care Clin N Am 2005, 11(1):35–44.
   Google Scholar